Abstract: Objective To study the efficacy and safety of transcatheter arterial chemoembolization（TACE） plus Sorafenib in hepatic carcinoma.Methods 92 hepatic carcinoma patients treated from September 2015 to June 2017 in our hospital were selected.Patients were grouped by random number table，46 cases each group.The control group was treated with TACE； the observation group was treated with TACE plus Sorafenib.The therapeutic effect，hepatic function，life quality and adverse reactions were probed.Results The total effective rate in the observation group（52.17%） was significantly higher than control group（36.96%）（P＜0.05）； before treatment，the index of TBIL（total bilirubin），ALT（alanine aminotransferase） and ALB（albumin） showed no statistical differences（P＞0.05）；after treatment，the values of TBIL，ALT and ALB in the observation group were lower than control group； the related index in the control group were significantly higher than before（P＜0.05）； before treatment，the ADL（activity of daily living） scores showed no statistical differences（P＞0.05）；after treatment，the ADL scores in the observation group were higher than control group（P＜0.05）； the adverse event rate in the observation group（24 cases） and control group（21 cases） showed no statistical differences（P＞0.05）.Conclusion The TACE plus Sorafenib can increase the therapeutic effect，reduce the hepatic injury，improve the life quality and decrease the adverse event rate.The safe and reliable therapy is worthy of clinical application and promotion.

Key words: Sorafenib, hepatic carcinoma, percutaneous hepatic artery chemoembolization, safety